Kymera Therapeutics (NASDAQ:KYMR) Lowered to Sell Rating by Wall Street Zen

Kymera Therapeutics (NASDAQ:KYMR) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other brokerages also recently issued reports on KYMR. Morgan Stanley restated an “overweight” rating and set a $123.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, February 26th. Royal Bank Of Canada reissued an “outperform” rating and set a $108.00 target price on shares of Kymera Therapeutics in a research report on Thursday, February 26th. HC Wainwright raised their price target on shares of Kymera Therapeutics from $84.00 to $134.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Citigroup boosted their price target on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Bank of America upped their price objective on shares of Kymera Therapeutics from $71.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $119.50.

Kymera Therapeutics Stock Down 0.0%

NASDAQ KYMR opened at $83.49 on Friday. The company has a market capitalization of $6.82 billion, a price-to-earnings ratio of -22.69 and a beta of 2.20. Kymera Therapeutics has a twelve month low of $19.44 and a twelve month high of $103.00. The stock has a fifty day simple moving average of $78.80 and a 200 day simple moving average of $66.80.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The company had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. During the same period in the previous year, the firm posted ($0.88) earnings per share. The firm’s quarterly revenue was down 60.8% compared to the same quarter last year. Research analysts expect that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Jeremy G. Chadwick sold 3,919 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $85.30, for a total transaction of $334,290.70. Following the transaction, the chief operating officer directly owned 73,810 shares of the company’s stock, valued at approximately $6,295,993. This represents a 5.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bruce Booth sold 81,866 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $90.13, for a total value of $7,378,582.58. Following the completion of the transaction, the director owned 675,341 shares in the company, valued at approximately $60,868,484.33. The trade was a 10.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 561,698 shares of company stock worth $50,388,337 over the last three months. Insiders own 16.01% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

A number of large investors have recently modified their holdings of the company. US Bancorp DE grew its position in Kymera Therapeutics by 9.8% in the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after purchasing an additional 166 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Kymera Therapeutics by 9.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock worth $156,000 after buying an additional 248 shares during the last quarter. Larson Financial Group LLC raised its holdings in Kymera Therapeutics by 36.9% during the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after buying an additional 287 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its stake in shares of Kymera Therapeutics by 3.3% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 12,655 shares of the company’s stock valued at $985,000 after buying an additional 410 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in shares of Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after buying an additional 424 shares in the last quarter.

Kymera Therapeutics News Summary

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near‑term loss forecasts (small EPS improvements across Q1–Q4 2026), kept a “Buy” rating and reiterated a $134 price target — this reinforces constructive analyst sentiment and supports buying interest. Read More.
• Positive Sentiment: UBS and several peers have raised price targets (UBS to $128, Barclays/Oppenheimer/Mizuho also higher), signaling consensus analyst optimism around Kymera’s pipeline progress as a medium‑term catalyst. Read More.
• Positive Sentiment: Another outlet reported a price‑target bump to $100 — additional upward target revisions help underpin sentiment even as valuation remains tied to clinical milestones. Read More.
• Positive Sentiment: Coverage highlights a healthy cash runway (~$1.6B reported) and upcoming program milestones (KT‑579 data in 2H26; KT‑621 Phase 2b readouts in 2027) that are the primary value drivers for this clinical‑stage biotech. Read More.
• Neutral Sentiment: Technical/contextual note — KYMR is trading above its 200‑day moving average with elevated volatility (beta ~2.2); analyst average targets remain well above current levels, which can amplify momentum in either direction. Read More.
• Negative Sentiment: Large director sale: Director Bruce Booth sold 81,866 shares (~$7.38M at ≈$90), a material single‑day disposal that can be perceived as profit‑taking and may cap short‑term upside. Read More.
• Negative Sentiment: Multiple senior insiders (CFO Bruce Jacobs, COO Jeremy Chadwick, Jared Gollob and others) disclosed sales across March 2–4 at roughly $85–$89, each trimming holdings by a few percent — repeated insider selling increases short‑term supply and investor caution. Read More.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.